Opinion|Videos|June 18, 2024
Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care
The panelists share their concluding thoughts on the importance of collaboration between academic and community practices to achieve the best outcomes for their patients, which includes seeking second opinions and incorporating insights from tumor board discussions.
Advertisement
Video content above is prompted by the following questions:
- When a new eBC product is approved, what is done prior to prepare from an operational standpoint?
- Are there instances when a new eBC product is approved and it’s not worth operationalizing?
- How can academic centers work efficiently with community practices in the management of patients with eBC?
- Scimeca: How might the approval of targeted therapies affect treatment paradigms for eBC?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Understanding the Risk of Second Primary Cancers After Early Breast Cancer
September 16th 2025
- Oral SERDs in Breast Cancer: Imulnestrant and Elacestrant
August 27th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
4
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
5